STAT3 and cancer: Using the JAK pathway inhibitor ruxolitinib to inhibit IL6/STAT3 signaling disrupts the ER-FOXA1-pSTAT3 enhancer-driven transcriptional program of target genes in breast cancer and suppresses the invasive capacity of cancer cells [301].